Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2022.175051 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2022.175051 35618037!9124632!35618037     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Pharmacol 2022 ; 927 (ä): 175051 Nephropedia Template TP {{tp|p=35618037|t=2022. Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 |pdf=|usr=}}{{35618037}} gab.com Text Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=35618037 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, including 5.95 million deaths, were reported to the world health organization (WHO). No specific treatment is currently available for COVID-19, and the discovery of effective therapeutics requires understanding the effective immunologic and immunopathologic mechanisms behind this infection. Type-I interferons (IFN-Is), as the critical elements of the immediate immune response against viral infections, can inhibit the replication and spread of the viruses. However, the available evidence shows that the antiviral IFN-I response is impaired in patients with the severe form of COVID-19. Moreover, the administration of exogenous IFN-I in different phases of the disease can lead to various outcomes. Therefore, understanding the role of IFN-I molecules in COVID-19 development and its severity can provide valuable information for better management of this disease. This review summarizes the role of IFN-Is in the pathogenesis of COIVD-19 and discusses the importance of autoantibodies against this cytokine in the spreading of SARS-CoV-2 and control of the subsequent excessive inflammation. Twit Text FOAVip Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=35618037 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35618037 #FOAvip English Wikipedia <ref>{{Cite pmid|35618037}}</ref> Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 #MMPMID35618037 Khorramdelazad H; Kazemi MH; Azimi M; Aghamajidi A; Mehrabadi AZ; Shahba F; Aghamohammadi N; Falak R; Faraji F; Jafari R Eur J Pharmacol 2022[Jul]; 927 (ä): 175051 PMID35618037show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, including 5.95 million deaths, were reported to the world health organization (WHO). No specific treatment is currently available for COVID-19, and the discovery of effective therapeutics requires understanding the effective immunologic and immunopathologic mechanisms behind this infection. Type-I interferons (IFN-Is), as the critical elements of the immediate immune response against viral infections, can inhibit the replication and spread of the viruses. However, the available evidence shows that the antiviral IFN-I response is impaired in patients with the severe form of COVID-19. Moreover, the administration of exogenous IFN-I in different phases of the disease can lead to various outcomes. Therefore, understanding the role of IFN-I molecules in COVID-19 development and its severity can provide valuable information for better management of this disease. This review summarizes the role of IFN-Is in the pathogenesis of COIVD-19 and discusses the importance of autoantibodies against this cytokine in the spreading of SARS-CoV-2 and control of the subsequent excessive inflammation. |*COVID-19 Drug Treatment[MESH] |*Interferon Type I/therapeutic use[MESH] |Cytokines[MESH] |Humans[MESH]Type-I interferons in the immunopathogenesis and treatment of Coronavi(epmc).pdf DeepDyve Pubget Overpricing